Pre-made Erlizumab benchmark antibody (Whole mAb, anti-ITGB2 therapeutic antibody, Anti-CD18/LAD/LCAMB/LFA-1/MAC-1/MF17/MFI7 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-844

Anti-ITGB2 therapeutic antibody (Pre-made Erlizumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Erlizumab, also known as rhuMAb, is a recombinant humanized monoclonal antibody that was an experimental immunosuppressive drug. Erlizumab was developed by Genentech under a partnership with Roche to treat heart attack, stroke, and traumatic shock.[1]

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-844-1mg 1mg 3090
GMP-Bios-INN-844-10mg 10mg Inquiry
GMP-Bios-INN-844-100mg 100mg Inquiry
GMP-Bios-INN-844-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Erlizumab Biosimilar, Whole Mab, Anti-Itgb2 Antibody: Anti-CD18/LAD/LCAMB/LFA-1/MAC-1/MF17/MFI7 therapeutic antibody
INN Name Erlizumab
TargetITGB2
FormatWhole mAb
DerivationHumanized
Species Reactivityhuman
CH1 IsotypeIgG1 - nd
VD LCIgG1 - nd
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies0
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0